Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05539768 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor

Start date: October 8, 2022
Phase: Early Phase 1
Study type: Interventional

Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.

NCT ID: NCT05532696 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Start date: September 27, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)

NCT ID: NCT05525858 Recruiting - Solid Tumor Clinical Trials

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

KOSMOSII
Start date: September 28, 2022
Phase:
Study type: Observational

A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using targeted and/or immunotherapies outside of the approved indications via local clinical practice (Tier 1 & 2) and clinical trials (Tier 3)

NCT ID: NCT05525559 Not yet recruiting - Clinical trials for Advanced Solid Tumor

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

FIRST
Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors. It is anticipated that approximately 34 subjects will be enrolled in the dose-escalation phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.

NCT ID: NCT05525455 Terminated - Cancer Clinical Trials

TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)

Start date: August 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.

NCT ID: NCT05525247 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Start date: December 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.

NCT ID: NCT05522309 Recruiting - Clinical trials for Advanced Solid Tumor

FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors

FLIGHT
Start date: August 30, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0111 in patients with advanced solid tumors. It is anticipated that approximately 37 subjects will be enrolled in the dose-escalation phase of the study. ET0111 will be administered orally once daily (QD) in 21-day treatment cycles.

NCT ID: NCT05518253 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

NCT ID: NCT05518045 Recruiting - Clinical trials for Advanced Solid Tumor

Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Start date: August 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, open-Label, dose-Escalation and dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in combination with Toripalimab in Advanced Solid Tumours.

NCT ID: NCT05515185 Not yet recruiting - Clinical trials for Advanced Solid Tumor

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

Start date: September 9, 2022
Phase: Early Phase 1
Study type: Interventional

This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.